Isotechnika Pharma Inc IPHAF

Psoriasis drug “slows dementia”

[macbethorfaust]

www.bbc.co.uk/news/health-20463370

Doesn't say what drug was used except that it was injected (which maybe for mice you have to anyway). If, as appears plausible, it's the general anti rejection effect that has the benefit as opposed to something coincidentally specific to the drug itself, then maybe a low NODATdrug like ISA will have a leg up.

[throughmud]

Macfaust, my guess is that the drug referred to in the BBC article is most likely to be one based on IL-17 inhibition like the new IL-17 inhibitor MABs that are in Phase 3 testing for psoriasis.   mud

[throughmud]

Could be brodalumab, ixekizumab, secukinamab. All moving ahead in Phase 3, each could be looking for approval in the next couple of years, possibly. Apparently there are subsets of IL-17 so one or two of these might work better than the others. The biochemistry of interleukins and there role in human diseases and inflammation have come to light over the past five years. Ustekinumab (IL-12 and IL

[macbethorfaust]

well, I would be surprised if they were using drugs that weren't approved yet even though its just mice. I am guessing its some approved biologic or possiblly, since this is Europe, could even by cyclosporine

[throughmud]

Macbethorfaust, it turns out that the psoriasis "drug" that may help with Alzheimer's is ustekinumab, aka Stelara, currently being used in psoriasis treatment. Standard regimen for psoriasis is injection once every 12 weeks. mud

[macbethorfaust]

Thanks throughmud.  Looks like not much releveance then to ISA.  

[throughmud]

I think the relevance for Isotechnika was more clear and immediate two to three years ago (with lasting effects) when the new biologics were added to the package for treatment of psoriasis. These seem to have made calcineurin inhibitors more or less redundant for the treatment of psoriasis. mud